



E-ISSN: 2616-3470  
P-ISSN: 2616-3462  
© Surgery Science  
www.surgeryscience.com  
2019; 3(1): 280-284  
Received: 14-11-2018  
Accepted: 18-12-2018

**Dr. P Siva Karthik**  
Vinayaka Missions Medical College & Hospital, Karaikal Puducherry, Vinayaka Missions Research Foundation (Deemed To Be University), Puducherry, India

**Dr. Balasundaram**  
Vinayaka Missions Medical College & Hospital, Karaikal Puducherry, Vinayaka Missions Research Foundation (Deemed To Be University) Puducherry, India

**Dr. Ranjit Kumar**  
Vinayaka Missions Medical College & Hospital, Karaikal Puducherry, Vinayaka Missions Research Foundation (Deemed To Be University) Puducherry, India

## Assessment of estrogen receptor, progesterone receptor of infiltrating ductal carcinoma of breast for neoadjuvant chemotherapy

**Dr. P Siva Karthik, Dr. Balasundaram and Dr. Ranjit Kumar**

DOI: <https://doi.org/10.33545/surgery.2019.v3.i1e.48>

### Abstract

**Background:** The aims and objectives of this study are to study the influence of Estrogen receptor ER, Progesterone receptor PR of patients having infiltrating ductal carcinoma of breast receiving Neoadjuvant chemotherapy, To study the influence of ER and PR receptors in patients receiving neoadjuvant chemotherapy & correlate complete pathological response.

### Methods

- **Type of study:** Prospective clinical study. present study was carried out in the department of general surgery Vinayaka Missions medical college and hospital karaikal from July 2016 – December 2017.
- HPE (Histopathological examination) and ER PR status was done. Patients diagnosed with locally advanced breast cancer underwent simple randomization into 2 treatment groups.

**Group 1:** AC (Adriamycin 60mg/m<sup>2</sup>, Cyclophosphamide 600mg/m<sup>2</sup>) once every 3 weeks for 4 cycles

**Group2:** Docetaxel 75 mg/m<sup>2</sup> for 4 cycles every 3 weekly(11).

Clinical examination was performed after every two cycles and completing all the chemotherapy, study group patients were subjected to Modified radical mastectomy which was then followed by evaluation of pathological response.

**Conclusion:** In this study 30 patients ER PR status was done. According to ER PR status Neoadjuvant chemotherapy regimen given. NCT response was assessed with clinical / imaging study. There was reduction in tumor size and change in lymph node status in both the groups with p value of .44. As our study size is small we cannot predict the actual outcome of the two study groups. We need larger sample size to predict the actual outcome.

**Results:** The statistical analysis was performed by STATA 11.2. Descriptive statistics of frequency and percentage were performed all the study variables. Chi square test were used to measure the association between the CP response with ER status. *P*<0.05 considered as statistically significance.

**Keywords:** Mammography, neoadjuvant chemotherapy, downstaging, pathological complete response, birads, modified radical mastectomy, axillary node dissection

### Introduction

- Cancer is often considered as a disease of affluences but about 70% deaths due to cancer occur in the low and middle income countries.
- Leading cause of death in many wealthy countries and its toll is rising in poor regions.
- Breast cancer is a cancer that develops in the cells of breast of men and women. Worldwide breast cancer is the second most common cancer after lung cancer and fifth most common cause of cancer death.

It's a multifactorial disease. Approximately 40,000 women die of breast cancer each year. Carcinoma breast is the second commonest malignancy of females next to cervical cancer. It's responsible for about 20% of female cancer deaths.

**Table 1:** Comparison of Incidence and Mortality of Breast cancer in India and World in 2012(1)

Age standardized rate (per 100000)	India	World
Incidence	25.8	43.3
Mortality	12.7	12.9


**Correspondence**  
**Dr. P Siva Karthik**  
Vinayaka Missions Medical College & Hospital, Karaikal Puducherry, Vinayaka Missions Research Foundation (Deemed To Be University) Puducherry, India

- Nowadays breast cancer is predicted largely on the result of randomized prospective clinical trials.
- Mortality in Breast cancer can be controlled by screening, neoadjuvant systemic therapy, adjuvant radiotherapy.
- Better outcomes are expected as we make a framework from investigations through new therapies. The optimal management of LABC encompasses combined-modality therapy with Neoadjuvant Chemotherapy (NACT) comprising Anthracyclines and Taxane based regimen, followed by loco regional therapy (surgery and radiation) and hormonal and targeted therapy where ever necessary (4).
- The advantages of NACT in LABC include (5) :
  - Targeting distant micro metastases
  - Down staging of the primary tumour, which increase the chance of resectability and also Breast Conservation surgery [BCS] whenever possible.
  - In-vivo response of chemotherapy can be assessed because of increased drug delivery through intact vasculature.
- When cancer occurs in the breast of woman under forty it is more rapid in progress than when the patient is older, and also more extensive. Remote sympathy likewise takes place more readily in them than in the old, so that the operation success better in the latter on this account. – John Hunter (1728-1793)
- Breast cancer development and regression involves complex interaction between hormone receptors and transcriptional profile of ER+ PR+, ER - PR- tumors is the main discriminative factor for breast cancer phenotype, breast cancer remains more heterogenous with different phenotypes.
- The result of various different growth regulator pathways that could be activated and the possibility that virtually all signalling pathways can cross talk underlying the complexity of progression. Tumour cells are able to produce growth factors by autocrine means and frequently express several classes of growth factor receptors and their down streaming signalling elements.

disease) based on the RECIST criteria 1.1. Pathological complete response (pCR) defined as absence of invasive cancer component in breast and axillary lymph nodes resected specimen.


**Results**

**Consort Diagram of Study Population**



Receptor status

	Number of Cases	Percentage
ER +	18	60%
ER -	12	40%
Total	30	



1) Receptor status showing Number of ER+ and ER-ve individuals with pie diagram.

**Methods**

The purpose of this thesis is to study and report the observations made on the cases of cancer breast in Vinayaka Missions medical college from July 2016 to august 2018.

**Inclusion criteria:** Newly diagnosed and histologically proven locally advanced breast carcinoma.


**Exclusion Criteria:** Diagnosis of benign breast disease, Birads 1, 2,. Male breast cancer patients, Patients with other malignancies, Pregnant women with breast cancer.

**Definition of end points**

Response to NACT defined as CR (Complete response), PR (Partial response), SD (Stable disease) and PD (Progressive

2) Neoadjuvant Chemotherapy cycle 1

	ER +		ER -	
	CYC + ADR	%	Docetaxel	%
Complete				
Partial	6	33.3%	4	33.3%
Progressive	3	16.67%	6	50.0%
Stable	9	50.00%	2	17%
Total	18		12	




2) Bar chart and table showing Pathological response after first cycle of chemotherapy

In this study group of 30 patients 18 patients are ER+ and 12 Patients are ER -ve. The former are started with CYC+ADR and the latter are started with Docetaxel respectively. In ER +ve group out of 18, 6 patients (33%) showed partial response, 9 (50%) showed stable response, and 3 (17%) showed Progressive response.

In ER-Ve group out of 12 patients 4 (33.3%) showed partial response, 2 patients (16.67%) showed stable response and 6 patients (50%) showed progressive response.

3) Neo adjuvant chemotherapy cycle II

	ER +			P-Value	ER -
	CYC + ADR	docetaxel	Docetaxel		
Complete				0.407	
Partial	7 (47%)	1 (33.3%)			5 (42%)
Progressive	1 (7%)	1 (33.3%)			5 (42%)
Stable	7 (47%)	1 (33.3%)			2 (16%)
Total	15	3			12



3) Bar chart and table showing Pathological response after Second cycle of chemotherapy


In this cycle out of 18 patients in ER + ( CYC + ADR) 7 (47%) patients showed partial response, 7 (47%) showed stable response, 1 (7%) patients showed progressive response & those who were given docetaxel 1 patient (33.33%) showed partial response, 1 (33.33%) patient showed progressive response, 1 patients (33.33%) showed stable response

Out of 12 ER-ve (DOCETAXEL) patients 5 (42%) patients showed partial response 2 (16%) showed stable response and 5 (42%) showed progressive response.

4) Neoadjuvant

Chemotherapy Cycle III

	ER+			ER -	
	CYC + ADR	Docetaxel	P-Value	Docetaxel	%
Complete	3 (19%)		0.731	5	42%
Partial	9 (56%)	1 (50%)		2	16%
Progressive	1 (6%)			4	34%
Stable	3 (19%)	1 (50%)		1	8%
Total	16	2		12	




4) Bar chart and table showing Pathological response after third cycle of chemotherapy

Out of 18 ER +VE 3 (19%) showed complete response, 9 patients (56%) showed partial response, 1 patient showed progressive response, 3 patients showed stable response and 1 patient who was given Docetaxel also shown Partial response. 1 patients (50%) showed stable response with Docetaxel. The p value was calculated to be .731 among the two groups.

Out of 12 ER -VE 5 (42%) showed complete response, 2 (16%) showed partial response, 1 patient (8%) showed stable response & 4 (34%) patients showed Progressive response.

5) Neoadjuvant chemotherapy cycle IV

	ER+			P-Value	ER-
	CYC + ADR	Docetaxel	Docetaxel		
Complete	4 (27%)			0.081	4 (42%)
Partial	9 (60%)	1 (33.3%)			3 (27%)
Progressive		1 (33.3%)			4 (27%)
Stable	2 (13%)	1 (33.3%)			1 (9%)
Total	15	3			12




5) Bar chart and table showing Pathological response after fourth cycle of chemotherapy

In 18 ER +Ve patients, out of 15 patients who were given CYC + ADR, 4 (27%) patients showed complete response, 9 (60%) patients showed partial response, 2 (13%) patients showed stable response, In 3 Patients who were given DOCETAXEL 1 (33.33%) showed complete response, 1 (33.33%) showed partial response, and 1 patient (33.33%) showed progressive response. P value was noted to be 0.81

In 12 ER-ve patients who were given DOCETAXEL 5 patients (42%) showed complete response, 3 (27%) showed partial response, 1 patient (9%) showed stable response. 3 patients (27%) showed progressive response.

6) Adverse Reactions after four cycles of chemotherapy


	Number	%
Nil	15	50%
Nausea	9	30%
Vomiting	4	13%
Neutropenia	2	7%



Out of the 30 patients 15 patients were asymptomatic and 15 patients showed adverse reactions. Out of them 9 patients 30% gave complaints of nausea and 4 patients (13%) gave complaints of vomiting. 2 patients (7%) had neutropenia.

7) ER+ve: Pathological response

complete	
partial	11 (64%)
stable	4 (13.33%)
progressive	1 (3.33%)
total	17




7) Bar diagram showing Pathological response in ER+ ve patients

In ER +ve patients 11 patients showed partial response, 4 patients showed stable response and 1 patients showed

progressive response.

8) ER-VE Pathological Response

Complete	3 (37.5%)
Partial	3 (37.5%)
Stable	2 (25%)
Progressive	0
Total	8



8) Bar diagram showing pathological response in ER -ve individuals

In ER \_ve patients 3 (37.5%) showed complete response, 3 (37.5%) showed partial response and 2 (25%) showed stable response.

Conclusion

- In this prospective hospital based study conducted in vinayaka mission medical college and hospital in the department of general surgery, we access the ER and PR of infiltrating ductal carcinoma of breast for neoadjuvant chemotherapy.
- We selected 40 patients with ca breast. 30 patients were selected according to inclusion and exclusion criteria with infiltrating ductal carcinoma. In that total study population, 18 were given cyclophosphamide and adriamycin chemotherapy regimen out of them those patients who didn't respond to CYC +ADR drug was changed to Docetaxel. In second group 12 patients were given docetaxel.
- Out of 18 patients in the first group 3 patients were not responded to adriamycin and cyclophosphamide, and the drug was changed to Docetaxel, out of this three patients 1 patient not responded to Docetaxel and was not operated. Other patients who underwent neoadjuvant therapy were operated.
- Out of 12 patients in group II 8 patients responded to neoadjuvant chemotherapy with Docetaxel and 4 patients showed progressive response and, the other patients were operated. Out of the 30 patients 15 patients were asymptomatic and 15 patients showed adverse reactions. Out of them 9 patients 30% gave complaints of nausea and 4 patients (13%) gave complaints of vomiting. 2 patients (7%) had neutropenia.
- Funding: No funding sources
- Conflict of interest: None declared
- Ethical approval: The study was approved by the Institutional Ethics Committee

References

1. Fact Sheets by Cancer [Internet]. [cited 2015 Feb 8].

- Available from:  
[http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)
2. Desai PB. Breast Cancer Profile in India: Experiences at the Tata Memorial Hospital, Bombay. In: Paterson AHG, Lees AW, editors. *Fundamental Problems in Breast Cancer* [Internet]. Springer US; 1987 [cited Feb 8]. 2015, 273–9. Available from:  
[http://link.springer.com/chapter/10.1007/978-1-4613-2049-4\\_32](http://link.springer.com/chapter/10.1007/978-1-4613-2049-4_32)
  3. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI *et al.* Revision of the American Joint Committee on Cancer Staging System for Breast Cancer. *J Clin Oncol.* 2002; 20(17):3628–36.
  4. Lena MD, Zucali R, Viganotti G, Valagussa P, Bonadonna G. Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer. *Cancer Chemother Pharmacol.* 1978; 1(1):53-9.
  5. Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. *The Oncologist.* 2006; 11(6):574-89.
  6. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. *J Natl Cancer Inst Monogr.* 2001; (30):96-102.
  7. Management of Locally Advanced Breast Cancer | Cancer Network [Internet]. 1997 [cited 2015 Feb 9]. Available from:  
<http://www.cancernetwork.com/review-article/management-locally-advanced-breast-cancer>
  8. Valero null, Buzdar null, Hortobagyi null. Locally Advanced Breast Cancer. *The Oncologist.* 1996; 1(1, 2):8-17.
  9. Management of Locally Advanced Breast Cancer | Cancer Network [Internet]. 1997 [cited 2015 Feb 9]. Available from:  
<http://www.cancernetwork.com/review-article/management-locally-advanced-breast-cancer>
  10. Gonzalez-Angulo AM, Hortobagyi GN. Inflammatory and Locally Advanced Breast Cancer. In: Jatoi DI, Kaufmann PDM, editors. *Management of Breast Diseases* [Internet]. Springer Berlin Heidelberg; [cited 2015 Feb 9]. 2010, 391–415. Available from:  
[http://link.springer.com/chapter/10.1007/978-3-540-69743-5\\_21](http://link.springer.com/chapter/10.1007/978-3-540-69743-5_21)
  11. *Surgical Oncology: An Algorithmic Approach* - Google Books [Internet]. [cited 2015Feb9]. Available from:  
<https://books.google.co.in/books?id=1cRL99H41iQC&pg=PA224&lpg=PA224&dq=Haagensen+C,+Stout+A.+Carcinoma+of+the+breast+II.+Criteria+of+operability.+Ann+Surg+1943;+118:859>
  12. Klefström P, Gröhn P, Heinonen E, Holsti L, Holsti P. Adjuvant postoperative radiotherapy, chemotherapy, and immunotherapy in stage III breast cancer. II. 5-year results and influence of levamisole. *Cancer.* 1987; 60(5):936-42.
  13. Derman DP, Browde S, Kessel IL, Moor NGD, Lange M, Dansey R *et al.* Adjuvant chemotherapy (CMF) for stage III breast cancer: A randomized trial. *Int J Radiat Oncol • Biol • Phys.* 1989; 17(2):257-61.
  14. Schaake-Koning C, Van Der Linden EH, Hart G, Engelsman E. Adjuvant chemo- and hormonal therapy in locally advanced breast cancer: a randomized clinical study. *Int J Radiat Oncol • Biol • Phys.* 1985; 11(10):1759-63.
  15. Rubens RD, Bartelink H, Engelsman E, Hayward JL, Rotmensz N, Sylvester R *et al.* Locally advanced breast cancer: The contribution of cytotoxic and endocrine treatment to radiotherapy: An EORTC breast cancer cooperative group trial (10792). *Eur J Cancer Clin Oncol.* 1989; 25(4):667-78.
  16. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P *et al.* Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update. *J Clin Oncol.* 2006; 24(12):1940-9.
  17. Kaufmann M, Minckwitz G von, Bear HD, Buzdar A, McGale P, Bonnefoi H *et al.* Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. *Ann Oncol.* 2007; 18(12):1927–34.
  18. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von Minckwitz G *et al.* Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. *J Clin Oncol Off J Am Soc Clin Oncol.* 2008; 26(5):814-9.